Mediwound (NASDAQ:MDWD) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.12, Fidelity Earnings reports. The firm had revenue of $5.14 million for the quarter, compared to analyst estimates of $2.67 million. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%.
MDWD traded down $0.02 during trading on Friday, reaching $3.05. The company’s stock had a trading volume of 67,300 shares, compared to its average volume of 39,031. Mediwound has a 1 year low of $2.55 and a 1 year high of $6.09. The company has a quick ratio of 3.99, a current ratio of 4.13 and a debt-to-equity ratio of 0.11. The firm has a fifty day simple moving average of $2.95 and a two-hundred day simple moving average of $3.44. The company has a market cap of $77.46 million, a price-to-earnings ratio of -6.22 and a beta of 0.48.
A number of research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.50 price target on shares of Mediwound in a research note on Friday. ValuEngine raised shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Oppenheimer decreased their price target on shares of Mediwound from $15.00 to $7.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Finally, Zacks Investment Research raised shares of Mediwound from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Wednesday, October 30th.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Recommended Story: Outstanding Shares
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.